Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9528503 | 0.81 | USP2 (0.45) | TAS1R3TAS1R1TAS1R2POLBMAPT | |
| SCHEMBL30977634 | 0.80 | CYP3A4 (0.48) | PTPN1GPR35MAPTNPC1RAB9A | |
| SCHEMBL11837453 | 0.76 | KMT2A (0.55) | PTPN1GPR35POLBMAPTNPC1 | |
| SCHEMBL12394016 | 0.73 | KDM4E (0.37) | TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2 | |
| SCHEMBL11732397 | 0.73 | PTPN1 (0.47) | PTPN1GPR35POLBMAPTNPC1 | |
| SCHEMBL11788981 | 0.72 | GPR35 (0.46) | PTPN1GPR35NPC1RAB9A | |
| SCHEMBL10906990 | 0.71 | EGFR (0.39) | TAS1R3TAS1R1TAS1R2POLBMAPT | |
| SCHEMBL596707 | 0.71 | KDM4E (0.52) | POLBMAPTSMN1; SMN2KMT2A | |
| SCHEMBL7282028 | 0.69 | CYP3A4 (0.55) | POLBMAPTJAK2TYK2KMT2A | |
| SCHEMBL18415560 | 0.69 | MAPT (0.51) | POLBMAPTSMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552077-B2 | Kidney disorders | EXOCELL, INC. | 2003-04-22 | — | — | US | disclosed |
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | EXOCELL, INC. | 2001-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | ALB, AGER, TTR | PTPN1 1419/4885GPR35 2832/4885TAS1R3 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.